Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 02:00:04 18/07/2024 pm IST			5-day change	1st Jan Change
92.51 ^EUR	+0.53%		-1.35%	+3.10%

10:00am	Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms	MT
07:46am	Sanofi: positive data for hemophilia in children	CF

Formation Biologics Inc. announced that it has received $372 million in funding from HongShan, Silicon Valley Venture Capital Corp., Sanofi

July 08, 2024

Formation Biologics Inc. announced that it has received $372 million in round of funding led by new investor Silicon Valley Venture Capital Corp. on July 8, 2024. The transaction included the participation from new investors HongShan and Sanofi.

Latest news about Sanofi

Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms	01:30pm	MT
Sanofi: positive data for hemophilia in children	11:16am	CF
Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms	09:21am	MT
Sanofi to invest $437 million in India global centre, double its workforce	17/07	RE
EU court criticizes Commission over handling of COVID vaccine contracts	17/07	RE
SANOFI : JP Morgan remains Neutral	16/07	ZD
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale	12/07	MT
Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports	12/07	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	11/07	RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season	11/07	CI
SANOFI : Receives a Sell rating from Deutsche Bank	10/07	ZD
SANOFI : UBS reiterates its buy recommendation	09/07	CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	09/07	MT
SANOFI : UBS maintains a Buy rating	09/07	ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours	09/07	MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy	09/07	CI
SANOFI : Jefferies maintains a Buy rating	08/07	ZD
SANOFI : Stifel slightly raises its target on the stock	08/07	CF
That's not so bad, is it?	08/07
Formation Biologics Inc. announced that it has received $372 million in funding from HongShan, Silicon Valley Venture Capital Corp., Sanofi	08/07	CI
Sector Update: Health Care Stocks Steady Premarket Friday	05/07	MT
Sector Update: Health Care	05/07	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	05/07	CI
Sanofi's Consumer Health Unit Receives Interest from French State	05/07	MT

Chart Sanofi

Duration

Period

More charts

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 04, 2024 at 01:31 am IST

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 05:28 pm IST

Sanofi : In the hot seat

October 30, 2023 at 04:22 pm IST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

92.02 EUR

Average target price

108.6 EUR

Spread / Average Target

+17.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+3.10%	126B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.46%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.57%	247B
NOVARTIS AG	+14.88%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Formation Biologics Inc. announced that it has received $372 million in funding from HongShan, Silicon Valley Venture Capital Corp., Sanofi

EPS Revisions